ZIVO Bioscience, Inc. (ZIVO)
USD 16.02
(-15.68%)
USD 16.02
(-15.68%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 71.96 Thousand USD | 105.31% |
| 2022 | -1.35 Million USD | 84.34% |
| 2021 | -8.64 Million USD | -265.72% |
| 2020 | 5.21 Million USD | 5.74% |
| 2019 | 4.93 Million USD | -72.23% |
| 2018 | 17.76 Million USD | 1.4% |
| 2017 | 17.52 Million USD | 78.75% |
| 2016 | 9.8 Million USD | 59.54% |
| 2015 | 6.14 Million USD | 53.4% |
| 2014 | 4 Million USD | 98.56% |
| 2013 | 2.01 Million USD | 56.58% |
| 2012 | 1.28 Million USD | 151.04% |
| 2011 | 513.14 Thousand USD | 106.05% |
| 2010 | 249.04 Thousand USD | -38.19% |
| 2009 | 402.91 Thousand USD | 144.39% |
| 2008 | 164.86 Thousand USD | -43.19% |
| 2007 | 290.21 Thousand USD | -40.17% |
| 2006 | 485.06 Thousand USD | 438.98% |
| 2005 | 89.99 Thousand USD | -84.16% |
| 2004 | 568.24 Thousand USD | 63590.61% |
| 2003 | -895.00 USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 640.44 Thousand USD | 789.98% |
| 2024 Q2 | 575.98 Thousand USD | -10.06% |
| 2023 Q2 | 1.48 Million USD | 97.96% |
| 2023 Q1 | 751.81 Thousand USD | 155.52% |
| 2023 FY | 71.96 Thousand USD | 105.31% |
| 2023 Q4 | 71.96 Thousand USD | 311.75% |
| 2023 Q3 | 17.47 Thousand USD | -98.83% |
| 2022 Q3 | -2.78 Million USD | 34.57% |
| 2022 FY | -1.35 Million USD | 84.34% |
| 2022 Q1 | -5.58 Million USD | 35.36% |
| 2022 Q2 | -4.25 Million USD | 23.94% |
| 2022 Q4 | -1.35 Million USD | 51.32% |
| 2021 Q3 | -10.53 Million USD | -0.9% |
| 2021 Q1 | 5.27 Million USD | 1.03% |
| 2021 Q2 | -10.44 Million USD | -298.15% |
| 2021 FY | -8.64 Million USD | -265.72% |
| 2021 Q4 | -8.64 Million USD | 17.95% |
| 2020 FY | 5.21 Million USD | 5.74% |
| 2020 Q4 | 5.21 Million USD | -2.58% |
| 2020 Q1 | 5.21 Million USD | 5.72% |
| 2020 Q2 | 5.23 Million USD | 0.34% |
| 2020 Q3 | 5.35 Million USD | 2.32% |
| 2019 Q3 | 7.44 Million USD | -1.95% |
| 2019 Q1 | 19.7 Million USD | 10.94% |
| 2019 Q2 | 7.59 Million USD | -61.47% |
| 2019 Q4 | 4.93 Million USD | -33.72% |
| 2019 FY | 4.93 Million USD | -72.23% |
| 2018 Q2 | 15.24 Million USD | -17.33% |
| 2018 FY | 17.76 Million USD | 1.4% |
| 2018 Q4 | 17.76 Million USD | 0.55% |
| 2018 Q1 | 18.44 Million USD | 5.28% |
| 2018 Q3 | 17.66 Million USD | 15.86% |
| 2017 Q4 | 17.52 Million USD | 9.81% |
| 2017 FY | 17.52 Million USD | 78.75% |
| 2017 Q2 | 14.79 Million USD | 9.07% |
| 2017 Q1 | 13.56 Million USD | 38.36% |
| 2017 Q3 | 15.95 Million USD | 7.87% |
| 2016 Q1 | 6.61 Million USD | 7.74% |
| 2016 Q2 | 7.46 Million USD | 12.77% |
| 2016 Q3 | 8.95 Million USD | 19.97% |
| 2016 Q4 | 9.8 Million USD | 9.44% |
| 2016 FY | 9.8 Million USD | 59.54% |
| 2015 Q3 | 5.7 Million USD | 9.1% |
| 2015 Q4 | 6.14 Million USD | 7.68% |
| 2015 Q1 | 4.66 Million USD | 16.5% |
| 2015 FY | 6.14 Million USD | 53.4% |
| 2015 Q2 | 5.22 Million USD | 12.08% |
| 2014 FY | 4 Million USD | 98.56% |
| 2014 Q4 | 4 Million USD | 23.95% |
| 2014 Q1 | 2.47 Million USD | 22.57% |
| 2014 Q2 | 2.83 Million USD | 14.53% |
| 2014 Q3 | 3.23 Million USD | 14.11% |
| 2013 FY | 2.01 Million USD | 56.58% |
| 2013 Q3 | 1.79 Million USD | 5.77% |
| 2013 Q2 | 1.69 Million USD | 3.25% |
| 2013 Q4 | 2.01 Million USD | 12.48% |
| 2013 Q1 | 1.64 Million USD | 27.46% |
| 2012 FY | 1.28 Million USD | 151.04% |
| 2012 Q4 | 1.28 Million USD | 28.65% |
| 2012 Q3 | 1 Million USD | 47.16% |
| 2012 Q2 | 680.4 Thousand USD | 38.98% |
| 2012 Q1 | 489.58 Thousand USD | -4.59% |
| 2011 Q3 | 483.53 Thousand USD | 47.13% |
| 2011 Q4 | 513.14 Thousand USD | 6.12% |
| 2011 FY | 513.14 Thousand USD | 106.05% |
| 2011 Q2 | 328.63 Thousand USD | 10.06% |
| 2011 Q1 | 298.6 Thousand USD | 19.9% |
| 2010 Q1 | 99.49 Thousand USD | -75.88% |
| 2010 Q3 | 416.67 Thousand USD | 45.5% |
| 2010 Q4 | 249.04 Thousand USD | -40.23% |
| 2010 FY | 249.04 Thousand USD | -38.19% |
| 2010 Q2 | 286.37 Thousand USD | 187.84% |
| 2009 Q4 | 412.42 Thousand USD | 98.73% |
| 2009 Q1 | 246.56 Thousand USD | 49.56% |
| 2009 FY | 402.91 Thousand USD | 144.39% |
| 2009 Q2 | 259.62 Thousand USD | 5.3% |
| 2009 Q3 | 207.53 Thousand USD | -20.06% |
| 2008 Q1 | 58.69 Thousand USD | -79.77% |
| 2008 FY | 164.86 Thousand USD | -43.19% |
| 2008 Q4 | 164.86 Thousand USD | 21.2% |
| 2008 Q3 | 136.02 Thousand USD | 79.36% |
| 2008 Q2 | 75.83 Thousand USD | 29.2% |
| 2007 Q1 | -450.00 USD | -100.09% |
| 2007 FY | 290.21 Thousand USD | -40.17% |
| 2007 Q4 | 290.21 Thousand USD | -22.22% |
| 2007 Q3 | 373.14 Thousand USD | -8.78% |
| 2007 Q2 | 409.07 Thousand USD | 91005.11% |
| 2006 Q2 | 432.91 Thousand USD | -25.31% |
| 2006 FY | 485.06 Thousand USD | 438.98% |
| 2006 Q4 | 485.06 Thousand USD | 55.7% |
| 2006 Q3 | 311.54 Thousand USD | -28.03% |
| 2006 Q1 | 579.59 Thousand USD | 544.01% |
| 2005 Q2 | 1.14 Million USD | 20.69% |
| 2005 Q1 | 951.52 Thousand USD | 67.45% |
| 2005 Q4 | 89.99 Thousand USD | -87.14% |
| 2005 Q3 | 699.62 Thousand USD | -39.08% |
| 2005 FY | 89.99 Thousand USD | -84.16% |
| 2004 FY | 568.24 Thousand USD | 63590.61% |
| 2004 Q4 | 568.24 Thousand USD | 2822.0% |
| 2004 Q3 | 19.44 Thousand USD | 103.3% |
| 2004 Q2 | -589.04 Thousand USD | -22451.61% |
| 2004 Q1 | -2612.00 USD | -191.84% |
| 2003 Q4 | -895.00 USD | 0.0% |
| 2003 FY | -895.00 USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 96.038% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 101.886% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 94.261% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 99.777% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 107.664% |
| Better Therapeutics, Inc. | -860 Thousand USD | 108.368% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 100.303% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 78.09% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 98.425% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 101.236% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 97.75% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 97.728% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 98.561% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 99.946% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | 59.831% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 99.417% |
| Molecular Templates, Inc. | 707 Thousand USD | 89.821% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 83.587% |
| NexImmune, Inc. | -3.13 Million USD | 102.296% |
| Orgenesis Inc. | 21.78 Million USD | 99.67% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 97.249% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 14550.201% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 101.528% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 157.766% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 99.935% |
| Statera Biopharma, Inc. | 14.41 Million USD | 99.501% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 100.947% |
| Trevena, Inc. | 2.25 Million USD | 96.813% |
| Vaxxinity, Inc. | 10.13 Million USD | 99.29% |
| Vaccinex, Inc. | -1.28 Million USD | 105.587% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | 79.108% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 99.456% |